Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
Authors
Keywords
Humoral Response, COVID-19, Multiple Sclerosis, Demyelinating Diseases, Immune Therapies
Journal
VACCINE
Volume 39, Issue 41, Pages 6111-6116
Publisher
Elsevier BV
Online
2021-09-02
DOI
10.1016/j.vaccine.2021.08.078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
- (2021) Mahsa Khayat-Khoei et al. JOURNAL OF NEUROLOGY
- Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
- (2021) Brian J Boyarsky et al. ANNALS OF THE RHEUMATIC DISEASES
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations
- (2021) Hubert Mado et al. JOURNAL OF NEUROLOGY
- Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
- (2021) I. Smets et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
- (2021) N.R. Oksbjerg et al. Multiple Sclerosis and Related Disorders
- COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
- (2020) D. Baker et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- An Italian programme for COVID-19 infection in multiple sclerosis
- (2020) Maria Pia Sormani LANCET NEUROLOGY
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
- (2020) Céline Louapre et al. JAMA Neurology
- Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples
- (2020) David M Manthei et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 in ocrelizumab-treated people with multiple sclerosis
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search